The drugmaker reported total sales last year increased 36% to $33.7 billion on a currency-adjusted basis as Ozempic sales jumped 66% and Wegovy sales surged 420%. Novo Nordisk has struggled to keep up with demand and has committed to spending $9 billion on new capacity. The risk here is there are potentially severe side effects from the drugs, including gallbladder disease and mental health issues. That poses a risk for the pharma stock as almost 93% of revenue is tied to diabetes and obesity, with 55% of the total coming from Ozempic and Wegovy. Any adverse indications could blow a hole in Novo Nordisk's business.